Cardiac sympathetic denervation for refractory ventricular arrhythmias

Cardiac sympathetic denervation (CSD) is an established rescue and adjunctive treatment for selected patients with recurrent ventricular tachycardia (VT), ventricular fibrillation (VF), or electrical storm. By reducing sympathetic input to the heart, the operation aims to lower the trigger burden when antiarrhythmic medication, catheter ablation, and implantable cardioverter-defibrillator (ICD) therapy have not provided durable control.

The procedure is most often considered within a specialist electrophysiology service, where cardiologists, cardiac surgeons, anaesthetists, genetic specialists, and heart-failure clinicians can assess the cause and reversibility of the arrhythmia. In Australia, this usually means referral to a tertiary centre in Sydney, Melbourne, Brisbane, Perth, or Adelaide, with careful coordination for patients travelling from regional and remote communities.

Why sympathetic denervation can help

The autonomic nervous system has a significant role in ventricular arrhythmogenesis. Increased sympathetic activity can shorten refractoriness, increase calcium loading, enhance triggered activity, and lower the threshold for VF. These effects are especially important in catecholaminergic polymorphic ventricular tachycardia (CPVT), long-QT syndrome, ischaemic cardiomyopathy, and some forms of arrhythmogenic cardiomyopathy.

CSD interrupts cardiac sympathetic signalling rather than removing the myocardial substrate itself. The operation commonly involves resection of the lower cervical and upper thoracic sympathetic chain, including the stellate ganglion and thoracic ganglia, although the exact technique varies. A left-sided procedure may be considered first in some settings, while bilateral denervation is often selected for severe disease, recurrent electrical storm, or inadequate response to unilateral treatment.

The goal is usually a meaningful reduction in VT episodes and ICD therapies, rather than a guaranteed cure. CSD may also reduce emergency presentations, repeated defibrillator shocks, sedation requirements, and the psychological distress associated with anticipating another shock. It should be viewed as part of a broader rhythm-control strategy rather than a replacement for an ICD when sudden-death risk remains high.

Selecting patients for the procedure

Patient selection begins with confirming that the rhythm is genuinely ventricular and clinically significant. Monomorphic VT, polymorphic VT, VF, and recurrent appropriate ICD therapies should be documented through device interrogation, electrocardiography, ambulatory monitoring, or stored electrograms. A fast atrial rhythm with aberrancy, supraventricular tachycardia, or inappropriate sinus tachycardia requires a different treatment pathway; this diagnostic criteria resource can help frame that distinction.

CSD is generally considered when arrhythmias remain refractory despite evidence-based therapy. Relevant measures may include beta-blockade, class I or III antiarrhythmic drugs, treatment of heart failure and ischaemia, catheter ablation, and correction of electrolyte or endocrine abnormalities. In CPVT and inherited channelopathies, specialist genetic assessment and maximally tolerated beta-blockade are central. Flecainide, left cardiac sympathetic denervation, and exercise modification may be appropriate in selected cases.

The clinical context matters. A patient with recurrent VT caused by an untreated coronary lesion may benefit more from revascularisation, while a patient with a dominant scar-related circuit may need repeat ablation. CSD becomes particularly attractive when VT is multifocal, haemodynamically poorly tolerated, inaccessible to ablation, or repeatedly triggered by adrenergic surges. Severe left ventricular dysfunction, advanced frailty, active infection, or an inability to tolerate thoracic surgery may shift the risk-benefit balance.

Assessing risk and readiness

Before surgery, the team should review imaging, coronary anatomy, ventricular function, medication adherence, renal and hepatic status, pulmonary disease, and prior thoracic procedures. ICD programming should be examined carefully, because inappropriate detection or avoidable antitachycardia pacing can exaggerate the apparent treatment failure. A complete medication and trigger review is equally important, including stimulant exposure, recreational drugs, fever, sleep deprivation, and missed beta-blocker doses.

Patients need a clear discussion about the expected outcome. CSD can reduce the frequency of arrhythmia and shocks, but recurrent VT remains possible and the ICD generally stays in place. Potential complications include Horner syndrome, compensatory sweating, pneumothorax, bleeding, infection, neuropathic pain, haemodynamic instability, and rarely phrenic or recurrent laryngeal nerve injury. Anaesthesia planning is particularly important in patients with unstable ventricular function or recent electrical storm.

Australian logistics should be addressed early. A patient from rural New South Wales, Queensland, or Western Australia may need temporary accommodation near a metropolitan hospital, assistance with transport, and a plan for postoperative review. Medicare coverage, state-based hospital pathways, private insurance, and the availability of thoracic surgical expertise can affect timing. The Therapeutic Goods Administration regulates medicines and devices, while the operation itself is delivered under state and territory health systems and local hospital governance.

Expected clinical results

Published studies are predominantly retrospective cohorts and systematic reviews rather than randomised trials. Across heterogeneous populations, bilateral or left-sided CSD has been associated with substantial reductions in VT burden and ICD shocks. Many series report that roughly half to two-thirds of patients remain free from recurrent sustained ventricular arrhythmia or receive a marked reduction in ICD therapies during follow-up, although estimates vary with disease type, follow-up duration, and the definition of success.

Results tend to be strongest when the arrhythmia is driven by sympathetic activation and when the procedure is performed before prolonged haemodynamic decline. In CPVT and long-QT syndrome, CSD can be particularly valuable for patients with recurrent syncope, aborted cardiac arrest, or ICD shocks despite medication. In structural heart disease, outcomes are more variable because scar progression, heart failure, and residual re-entry circuits can continue to generate VT.

Freedom from shocks is an important endpoint, but it should not be the only one. Clinicians may also assess total VT episodes, hospital admissions, electrical storms, left ventricular function, quality of life, exercise tolerance, medication burden, and survival. A successful procedure may produce a clinically important reduction without achieving complete arrhythmia suppression. Device interrogation at regular intervals is essential for detecting both symptomatic and silent events.

The Australian evidence base is developing through specialist electrophysiology networks and international collaboration. Clinicians and researchers can review current and past work in the journal’s arrhythmia article collection, including research on ablation, autonomic modulation, implantable devices, and inherited rhythm disorders. Such evidence is useful when counselling patients about the limits of observational data.

Integrating CSD with other treatments

CSD should be incorporated into a staged management plan. In an acute electrical storm, treatment may include sedation, intravenous antiarrhythmic therapy, beta-blockade, correction of potassium and magnesium, mechanical circulatory support in selected cases, and urgent catheter ablation. Temporary autonomic interventions, such as stellate ganglion blockade, can sometimes help stabilise a patient while the team evaluates definitive options.

After recovery, the underlying disease requires ongoing treatment. This may involve guideline-directed heart-failure therapy, coronary disease management, genetic counselling, family screening, repeat ablation, or adjustment of ICD detection zones and therapy settings. Exercise recommendations should be individualised. For people with CPVT or inherited syndromes, avoiding unsupervised high-intensity exertion and abrupt adrenergic stress may be important, while complete inactivity is not automatically appropriate.

Australian patients also need practical advice about driving and work. Austroads medical standards and state or territory licensing authorities apply specific restrictions after sustained VT, cardiac arrest, ICD shocks, and procedures. Commercial driving rules are generally more stringent than private-vehicle rules. The treating cardiologist should document advice clearly and provide a review plan, particularly for people whose employment involves remote travel, heavy machinery, emergency services, or water-based work.

Daily habits can influence recovery and symptom recognition. Regular medication timing is important for patients balancing early commutes, shift work, or outdoor activity in hot Australian summers. Dehydration, gastroenteritis, fever, and missed doses can increase arrhythmia vulnerability. Patients should know when to call 000, how to respond to an ICD shock, and which hospital has access to their device records and electrophysiology team.

Follow-up and long-term monitoring

Postoperative review should assess wound healing, respiratory symptoms, neurological signs, sweating changes, pain, blood pressure, and arrhythmia recurrence. Device interrogation can distinguish appropriate shocks, nonsustained episodes, lead problems, and programming issues. A reduction in shocks should be interpreted alongside ventricular function and heart-failure status, because the substrate may continue to evolve.

Follow-up is usually multidisciplinary and may include electrophysiology, inherited arrhythmia, heart failure, thoracic surgery, psychology, and cardiac rehabilitation services. Psychological support deserves attention: repeated ICD shocks can produce fear, avoidance, insomnia, and post-traumatic symptoms even when the rhythm has stabilised. Clear action plans and reliable access to the care team can improve confidence and reduce delayed presentation.

Research priorities include better selection criteria, standardised definitions of procedural success, comparisons between unilateral and bilateral approaches, and prospective evaluation of quality of life. More data are also needed for patients with advanced structural heart disease, paediatric channelopathies, and mixed arrhythmia mechanisms. Registries linking procedural details with ICD outcomes may help clarify which patients gain the greatest long-term benefit.

For clinicians, CSD is best considered neither a last-minute surgical gesture nor a routine escalation. It is a targeted autonomic intervention for carefully characterised, high-risk ventricular arrhythmia, delivered within an experienced service and integrated with ablation, medication, device therapy, and inherited disease management. For patients and families, timely referral can create an opportunity to reduce recurrent shocks and restore a safer, more predictable rhythm-care plan.

Explore the Journal of Arrhythmia’s research and educational resources, and share well-documented clinical experience through appropriate peer-reviewed publication to strengthen the evidence guiding autonomic therapy for refractory ventricular arrhythmias.